{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '8.2.3', 'Testosterone enanthate', '59', '8.2.4', 'Olaparib Labelling', '62', '8.2.5', 'Storage', '62', '8.2.6', 'Management of toxicity of olaparib', '62', '8.2.7', 'Management of hematological toxicity', '63', '8.2.7.1', 'Management of anemia', '63', '8.2.7.2', 'Management of neutropenia, leukopenia and thrombocytopenia', '64', '8.2.7.3', 'Management of prolonged hematological toxicities while on study', 'treatment', '64', '8.2.8', 'Management of non-hematological toxicity', '65', '8.2.8.1', 'Management of new or worsening pulmonary symptoms', '65', '8.2.8.2', 'Management of nausea and vomiting', '65', '8.2.8.3', 'Interruptions for intercurrent non-toxicity related events', '66', '8.3', 'Concomitant and post-study treatment(s)', '66', '8.3.1 Medications that may NOT be administered', '69', '8.4', 'Treatment compliance', '69', '9. ETHICAL AND REGULATORY REQUIREMENTS', '69', '9.1', 'Ethical conduct of the study', '69', '9.2', 'Ethics and regulatory review', '69', '9.3', 'Informed consent', '69', '9.4', 'Changes to the protocol and informed consent form', '70', '10.', 'STUDY MANAGEMENT', '70', '10.1 Training of study site personnel', '70', '10.2', 'Monitoring of the study', '70', '10.2.1', 'Source data', '71', '11. EVALUATION AND CALCULATION OF VARIABLES', '71', '11.1', 'Calculation or derivation of efficacy variable(s)', '71', '11.2', 'Calculation or derivation of safety variable(s)', '74', '11.2.1', 'Other significant adverse events (OAE)', '74', '11.3', 'Calculation or derivation of patient reported outcome variables', '74', '12. STATISTICAL METHODS AND SAMPLE SIZE DETERMINATION', '74', '12.1', 'Description of analysis sets', '74', '12.2', 'Methods of statistical analyses', '74', '12.2.1', 'Safety Analyses', '74', '12.2.2', 'Efficacy Analyses', '75', '12.2.3', 'Exploratory Analyses', '75', '12.3', 'Determination of sample size', '75', '4(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '13. IMPORTANT MEDICAL PROCEDURES TO BE FOLLOWED BY THE', 'INVESTIGATOR', '77', '13.1', 'Overdose', '77', '13.1.1', 'Paternal exposure', '77', '14.', 'LIST OF REFERENCES', '78', 'Appendix 1: Actions Required in Cases of Increases in Liver Biochemistry and', \"Evaluation of Hy's Law\", '85', 'Appendix 2: ECOG Performance Status', '90', 'Appendix 3:', 'Highly Effective Methods of Contraception', '91', 'Appendix 4: Quality of Life Surveys: FACT-P and IIEF', '92', 'Appendix 5: DNA Damage Repair Pathway Genes of Interest', '93', '5(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}